Skip to content
10-Q

Quarterly Report

PROMETHEUS BIOSCIENCES, INC.

0000950170-23-019768

← back to feed
Filed
May 9, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · May 1, 2023 47.81M sh
Shares Diluted Q3 2023 · Mar 31, 2023 47.46M sh
Shares Diluted Q3 2023 · Mar 31, 2022 39.01M sh
Capex Q3 2023 · Mar 31, 2023 $530K
Capex Q3 2023 · Mar 31, 2022 $955K
Operating Cash Flow Q3 2023 · Mar 31, 2023 −$39.54M
Operating Cash Flow Q3 2023 · Mar 31, 2022 −$29.39M
Short Term Investments Q3 2023 · Mar 31, 2023 $600.33M
Short Term Investments Q3 2023 · Dec 31, 2022 $403.33M
Cash And Equivalents Q3 2023 · Mar 31, 2023 $113.35M
Cash And Equivalents Q3 2023 · Dec 31, 2022 $292.42M
Stockholders Equity Q3 2023 · Mar 31, 2023 $697.62M
Stockholders Equity Q3 2023 · Dec 31, 2022 $675.97M
Stockholders Equity Q3 2023 · Mar 31, 2022 $206.72M
Stockholders Equity Q3 2023 · Dec 31, 2021 $235.16M
Current Liabilities Q3 2023 · Mar 31, 2023 $19.34M
Current Liabilities Q3 2023 · Dec 31, 2022 $22.82M
Total Liabilities Q3 2023 · Mar 31, 2023 $60.8M
Total Liabilities Q3 2023 · Dec 31, 2022 $64.81M
Current Assets Q3 2023 · Mar 31, 2023 $726.4M
Current Assets Q3 2023 · Dec 31, 2022 $708.15M
Total Assets Q3 2023 · Mar 31, 2023 $758.41M
Total Assets Q3 2023 · Dec 31, 2022 $740.77M
Eps Diluted Q3 2023 · Mar 31, 2023 −$0.86
Eps Diluted Q3 2023 · Mar 31, 2022 −$0.82
Eps Basic Q3 2023 · Mar 31, 2023 −$0.86
Eps Basic Q3 2023 · Mar 31, 2022 −$0.82
Sga Expense Q3 2023 · Mar 31, 2023 $13.39M
Sga Expense Q3 2023 · Mar 31, 2022 $8.09M
Rd Expense Q3 2023 · Mar 31, 2023 $36.42M
Rd Expense Q3 2023 · Mar 31, 2022 $27.93M
Net Income Q3 2023 · Mar 31, 2023 −$40.88M
Net Income Q3 2023 · Mar 31, 2022 −$32.07M
Operating Income Q3 2023 · Mar 31, 2023 −$48.7M
Operating Income Q3 2023 · Mar 31, 2022 −$32.1M
Revenue Q3 2023 · Mar 31, 2023 $1.11M
Revenue Q3 2023 · Mar 31, 2022 $3.92M